Stem cells to test medicines?

The British government and three big pharma companies announced a partnership today (October 3) to develop techniques for using linkurl:stem cells;http://www.the-scientist.com/2007/6/1/34/1/ to test the safety of new medicines, the linkurl:Financial Times reports.;http://www.ft.com/cms/s/0/ecdb2c48-714b-11dc-98fc-0000779fd2ac.html So far, the article notes, big companies have stayed away from the controversial field. The group, launched today as a nonprofit called Stem Cells for Safer Medicine

By | October 3, 2007

The British government and three big pharma companies announced a partnership today (October 3) to develop techniques for using linkurl:stem cells;http://www.the-scientist.com/2007/6/1/34/1/ to test the safety of new medicines, the linkurl:Financial Times reports.;http://www.ft.com/cms/s/0/ecdb2c48-714b-11dc-98fc-0000779fd2ac.html So far, the article notes, big companies have stayed away from the controversial field. The group, launched today as a nonprofit called Stem Cells for Safer Medicines (SC4SM), will fund five projects next year focused on turning stem cells into liver cells. Those liver cells would then be used to determine a compound's toxicity before it enters clinical trials. More than 90 percent of all drugs that enter clinical trials don't make it through tests of safety and efficacy, notes a linkurl:Reuters article;http://www.sciam.com/article.cfm?alias=glaxo-astra-roche-back-st&chanId=sa003&modsrc=reuters about the consortium. The idea behind the 5-year, $10 million project is to predict side effects that would doom medicines in development, before companies spend millions of dollars testing the compounds in early phase human trials. So far, the industry players are GlaxoSmithKline, Astra Zeneca and Roche, but more are expected to join in, according to the FT.

Popular Now

  1. How Plants Evolved Different Ways to Make Caffeine
  2. Thomson Reuters Predicts Nobelists
    The Nutshell Thomson Reuters Predicts Nobelists

    According to citation statistics, researchers behind programmed cell death pathways and CRISPR/Cas9 are among those in line for Nobel Prizes this year.

  3. Monsanto Buys Rights to CRISPR
    The Nutshell Monsanto Buys Rights to CRISPR

    The US agribusiness secures a global, nonexclusive licensing agreement from the Broad Institute to use the gene-editing technology for agricultural applications.

  4. Reviewing Results-Free Manuscripts
    The Nutshell Reviewing Results-Free Manuscripts

    An open-access journal is trialing a peer-review process in which reviewers do not have access to the results or discussion sections of submitted papers.

RayBiotech